Khaberni - The category of GLP-1 drugs, commercially known as "Ozempic" and "Mongaro", leads the global medical scene after their results exceeded the boundaries of blood sugar control and weight loss.
Here are 13 potential health benefits related to weight loss injections:
Protection of the kidneys from chronic complications
Clinical data confirm that "semaglutide" significantly reduced the risks of kidney failure and related complications in diabetic patients.
The U.S. Food and Drug Administration officially approved "Ozempic" in January 2025 for the treatment of chronic kidney diseases, after trials showed significant improvement not only dependent on weight loss but on direct protection mechanisms for the tissues.
Enhancing cardiovascular health
These drugs provide superior protection for the circulatory system, reducing the risks of strokes and heart attacks by 20% among those with obesity.
"Semaglutide" received official approval in March 2024 to reduce cardiac deaths, while "Tirzepatide" has proven highly efficient in improving heart muscle functions in patients with heart failure while maintaining ejection fraction.
Combatting fatty liver fibrosis (MASH)
Trials published in 2025 show significant improvements in advanced fatty liver cases, with liver fat percentage dropping by 31% in some groups.
Health authorities granted approval for these drugs to treat moderate and advanced liver fibrosis, providing a medical option for millions of adults suffering from liver scarring due to metabolic disorder.
Treatment of sleep apnea
The effectiveness of "Zebaund" is highlighted as the first officially approved treatment in December 2024 for cases of obstructive sleep apnea.
Studies have shown that the drug significantly improves nighttime breathing symptoms, reflecting the role of synthetic hormones in treating disorders resulting from severe obesity and narrow airways.
Protection from cognitive decline and dementia
Medical data involving millions of patients indicate that users of GLP-1 recorded lower risks of developing Alzheimer's disease and dementia compared to others.
Despite varying results from some major clinical trials, scientists are still researching these drugs' ability to reduce shrinkage of vital brain parts and protect nerves if used at early stages.
Reducing alcohol and addiction cravings
Current research targets the impact of these drugs on brain receptors linked to reward pathways and dopamine, helping curb cravings for addictive substances.
Extended studies have observed a 14% reduction in the risks of developing alcohol, nicotine, and opioid use disorders, with a notable decline in emergency cases related to overdoses.
Treating arthritis and rheumatism
These drugs open a new front against chronic inflammation that affects various body tissues and causes persistent pain.
Studies have shown that patients recorded a sharp decrease in knee pain and osteoarthritis inflammation, as the active substance modifies the immune response and reduces chemicals attacking healthy tissues.
Improving control over asthma attacks
Weekly injections help improve the life quality of patients with both asthma and obesity, according to analyses covering 60,000 patients in the United Kingdom.
Researchers believe the anti-inflammatory effect reduces the frequency of shortness of breath episodes, although no direct change was observed in lung mechanical functions, making it an indirect preventive measure.
Reducing the risks of cancer
Medical records indicate a close association between these drugs and reduced risks of 13 types of obesity-related cancers, including colon cancer.
The drugs enhance the activity of natural killer cells in the immune system, which may help prevent the migration or proliferation of cancer cells in early stages.
Reducing complications from COVID-19 infections
Scientific evidence shows that obese patients taking "Semaglutide" were 19% less likely to die when infected with the coronavirus.
This is due to the drug's ability to mitigate the severe inflammatory response caused by the virus, reducing serious respiratory complications that led to death during the pandemic.
Supporting fertility and reproduction chances
Medical reports recorded unexpected pregnancy cases among women who were suffering from infertility, known as the "Ozempic babies."
Doctors attribute this to the drug's ability to regulate female hormone levels and improve the quality of eggs, in addition to enhancing the movement and concentration of sperm in men with obesity.
Controlling polycystic ovary syndrome (PCOS)
These drugs treat disorders of polycystic ovaries by reducing excess testosterone levels and regulating menstrual cycle.
A study published in 2023 confirmed that low doses of "Semaglutide" succeeded in rebalancing hormones in 80% of female patients who did not respond to previous traditional treatments.
Silencing "food noise" in the brain
The drugs end intrusive thoughts and the persistent desire to eat by affecting hunger centers in the brain.
Trial data confirm that patients reported a sharp decline in the "reward" desire for eating, meaning that the medication reprograms the psychological relationship with food and reduces impulsive eating.
They also recorded a notable decrease in joint pain and knee inflammation, attributing this to the anti-irritation properties provided by these hormones, according to the "Washington Post".
Risks of sustainability and rebound effect
This medical breakthrough faces challenges related to the continuity of results, as evidence indicates that the health benefits may diminish once treatment is stopped, with potential weight regain within weeks.
A recent study warned that sudden cessation may raise the risks of heart attacks compared to continuing the medication, along with recording rare side effects like gastroparesis and osteoporosis, demanding patients to balance carefully between tangible benefits and long-term commitment.
